| A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up J Trouillas, P Roy, N Sturm, E Dantony, C Cortet-Rudelli, G Viennet, ... Acta neuropathologica 126, 123-135, 2013 | 521 | 2013 |
| European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas G Raverot, P Burman, A McCormack, A Heaney, S Petersenn, V Popovic, ... European journal of endocrinology 178 (1), G1-G24, 2018 | 519 | 2018 |
| Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial MR Gadelha, MD Bronstein, T Brue, M Coculescu, M Fleseriu, ... The lancet Diabetes & endocrinology 2 (11), 875-884, 2014 | 424 | 2014 |
| Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study AF Daly, MA Tichomirowa, P Petrossians, E Heliovaara, ML Jaffrain-Rea, ... The Journal of Clinical Endocrinology & Metabolism 95 (11), E373-E383, 2010 | 416 | 2010 |
| Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families AF Daly, JF Vanbellinghen, SK Khoo, ML Jaffrain-Rea, LA Naves, ... The Journal of Clinical Endocrinology & Metabolism 92 (5), 1891-1896, 2007 | 375 | 2007 |
| From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal SL Asa, O Casar-Borota, P Chanson, E Delgrange, P Earls, S Ezzat, ... Endocrine-related cancer 24 (4), C5-C8, 2017 | 332 | 2017 |
| Ketoconazole in Cushing's disease: is it worth a try? F Castinetti, L Guignat, P Giraud, M Muller, P Kamenicky, D Drui, P Caron, ... The Journal of Clinical Endocrinology & Metabolism 99 (5), 1623-1630, 2014 | 313 | 2014 |
| Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016 A McCormack, OM Dekkers, S Petersenn, V Popovic, J Trouillas, ... European Journal of Endocrinology 178 (3), 265-276, 2018 | 264 | 2018 |
| A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors A Wierinckx, C Auger, P Devauchelle, A Reynaud, P Chevallier, M Jan, ... Endocrine-related cancer 14 (3), 887-900, 2007 | 256 | 2007 |
| Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience G Raverot, N Sturm, F de Fraipont, M Muller, S Salenave, P Caron, ... The Journal of Clinical Endocrinology & Metabolism 95 (10), 4592-4599, 2010 | 250 | 2010 |
| Management of clinically non-functioning pituitary adenoma P Chanson, G Raverot, F Castinetti, C Cortet-Rudelli, F Galland, ... Annales d'endocrinologie 76 (3), 239-247, 2015 | 230 | 2015 |
| Sox3 Is Required for Gonadal Function, but Not Sex Determination, in Males and Females J Weiss, JJ Meeks, L Hurley, G Raverot, A Frassetto, JL Jameson Molecular and cellular biology 23 (22), 8084-8091, 2003 | 217 | 2003 |
| Clinical biology of the pituitary adenoma S Melmed, UB Kaiser, MB Lopes, J Bertherat, LV Syro, G Raverot, ... Endocrine reviews 43 (6), 1003-1037, 2022 | 191 | 2022 |
| How to classify pituitary neuroendocrine tumors (PitNET) s in 2020 J Trouillas, ML Jaffrain-Rea, A Vasiljevic, G Raverot, F Roncaroli, C Villa Cancers 12 (2), 514, 2020 | 187 | 2020 |
| Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal: Personal experience and review of the literature M Messerer, G Raverot, S Kassis, J Dubourg, V Lapras, J Trouillas, ... Neurosurgical focus 30 (4), E11, 2011 | 187 | 2011 |
| Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up G Raverot, A Wierinckx, E Dantony, C Auger, G Chapas, L Villeneuve, ... The Journal of Clinical Endocrinology & Metabolism 95 (4), 1708-1716, 2010 | 187 | 2010 |
| Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome M Pugeat, N Nader, K Hogeveen, G Raverot, H Déchaud, C Grenot Molecular and cellular endocrinology 316 (1), 53-59, 2010 | 180 | 2010 |
| Sox3 expression in undifferentiated spermatogonia is required for the progression of spermatogenesis G Raverot, J Weiss, SY Park, L Hurley, JL Jameson Developmental biology 283 (1), 215-225, 2005 | 178 | 2005 |
| Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1 D D'Angelo, D Palmieri, P Mussnich, M Roche, A Wierinckx, G Raverot, ... The Journal of Clinical Endocrinology & Metabolism 97 (7), E1128-E1138, 2012 | 177 | 2012 |
| Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment G Raverot, F Castinetti, E Jouanneau, I Morange, D Figarella‐Branger, ... Clinical endocrinology 76 (6), 769-775, 2012 | 177 | 2012 |
